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Abstract
This study explores the influence of baseline factors on first-month adherence to highly active
antiretroviral therapy (HAART) among adults. The study design involved a review of routinely
collected patient information in the CAPRISA AIDS Treatment (CAT) programme, at a rural and
an urban clinic in KwaZulu-Natal Province, South Africa. The records of 688 patients enrolled in
the CAT programme between June 2004 and September 2006 were analysed. Adherence was
calculated from pharmacy records (pill counts) and patients were considered adherent if they had
taken at least 95% of their prescribed drugs. Logistic regression was used to analyse the data and
account for confounding factors. During the first month of therapy, 79% of the patients were
adherent to HAART. HAART adherence was negatively associated with a higher baseline CD4
count. Women had better adherence if they attended voluntarily testing and counselling or if they
had taken an HIV test because they were unwell, while men had higher adherence if they were
tested due to perceived risk of HIV infection. HAART adherence was positively associated with
higher age among patients who possessed cell phones and among patients who provided a source
of income in the urban setting, but not in the rural setting. Though long-term data from this cohort
is required to fully evaluate the impact of non-adherence in the first month of treatment, this study
identifies specific groups of patients at higher risk for whom adherence counselling should be
targeted and tailored. For example, first-month HAART adherence can be improved by targeting
patients initiated on treatment with a high CD4 count.
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Introduction
Advances in highly active antiretroviral therapy (HAART) have dramatically reduced
morbidity and mortality due to AIDS (Kalichman, Ramachandran & Catz, 1999; Berg,
Demas, Howard, Schoenbaum, Gourevitch & Arnsten, 2004; Gill, Hamer, Simon, Thea &
Sabin, 2005). However, HAART includes complex drug regimens, which require strict
adherence to complicated schedules for the attainment of optimal long-term clinical and
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immunological response (Paterson, Swindells, Mohr, Brester, Vergis, Squier et al., 2000).
Strict adherence to all the antiretroviral (ARV) drugs prescribed is required for optimal
management of HIV infection (Chen, Hoy & Lewin, 2007). This strict adherence is one of
the most critical behavioural challenges in the treatment of HIV infections (Ferguson,
Stewart, Funkhouser, Tolson, Westfall & Saag, 2002). Adherence appears to be the strongest
predictor of both the durability of ARV medication (Esch, Klem, Kuhman, Hewitt & Morse,
2002) and the rate of cycling of the HAART regimen. Hence, it is imperative to evaluate the
effect of adherence comprehensively.
Recent studies on the impact of HAART adherence on treatment outcomes in sub-Saharan
Africa (in an era of treatment rollout) indicate improved immunologic response and clinical
outcomes among patients with optimal adherence (Abaasa, Todd, Ekoru, Kalyango, Levin,
Odeke & Karamagi, 2008; Chi, Cantrell, Zulu, Mulenga, Levy, Tambatamba et al., 2009).
Even after one month of therapy, patients with optimal adherence demonstrate a significant
increase in CD4 count, viral suppression and significant weight gain (Brechtl, Breitbart,
Galietta, Krivo & Rosenfeld, 2001). Moreover, it is shown that optimal initial adherence is
positively associated with improved long-term treatment outcomes (Carrieri, Raffi, Lewden,
Sobel, Michelet, Cailleton et al., 2003). These studies highlight the need for strict adherence
from the beginning of treatment in order to maintain prolonged clinical benefits. However,
clinicians are not able to accurately predict individuals at risk of suboptimal HAART
adherence at the beginning of treatment (Bangsberg, Hetch, Clague, Charlebois, Ciccarone,
Chesney & Moss, 2002). Since these individuals do not have a prior adherence track record,
patient-related factors (such as such as age, gender, income) and factors related to the
disease characteristics at baseline might prove to be informative predictors of initial and
future HAART adherence (Chesney, 2000; Reynolds, Testa, Marc, Chesney, Neidig, Smith
et al., 2004).
There is limited data regarding factors that predict initial optimal HAART adherence to
ARV medication. In particular, there are no studies that examine how patient-related factors
relate to each other (interact) and their subsequent influence on initial optimal HAART
adherence. The purpose of this study is to identify whether specific clinical and socio-
demographic factors present at baseline (and their respective possible interactions)
influenced first-month optimal adherence to HAART among HIV-positive adults. The
knowledge and understanding of such factors is particularly important given the increasing
number of patients enrolled on HAART who are to be maintained in therapy. Improved first-
month adherence could also help to avoid switching patients to more costly second-line
regimens. The findings will be useful in developing tools to assist clinicians in the
identification of factors related to poor adherence prior to initiating therapy. The results can




The Centre for the AIDS Programme of Research in South Africa’s (CAPRISA) AIDS
Treatment (CAT) programme is an ongoing rollout programme for ART services that was
started in 2004. The objective is to describe the profile of patients presenting at the CAT
programme with respect to their social characteristics, clinical status, and clinical course
during care, including HAART regime, HAART adherence and clinical outcomes. Adult
patients who met HAART eligibility criteria were enrolled into the CAT programme.
Eligibility criteria included a CD4 count below 200 cells/μL or patients with World Health
Organization (WHO) stage 4 of HIV disease, regardless of CD4 count. The accrual of
patients had been evenly distributed over time since initiation of the programme. All patients
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received three sessions of adherence education and motivation and preparedness training
prior to HAART initiation. These adherence counselling sessions were held one week prior
to starting treatment. The first two sessions were held the day the decision was taken to start
the patient on treatment, and the third session was held two or three days subsequent to the
first two sessions. All the sessions lasted 15 to 60 minutes, depending on the patient who is
counselled. The CAT programme offers HIV-care services at two different sites in
KwaZulu-Natal Province, namely the eThekwini Clinical Research Site located in an urban
area and the Vulindlela Clinical Research Site located in a rural area (see
<http://www.caprisa.org>). The programme started providing free HAART through a grant
from the US President’s Emergency Plan for AIDS Relief (PEPFAR) at a time when access
to HAART was limited.
All patients were on a regimen containing two nucleoside reverse transcriptase inhibitors
and one non-nucleoside reverse transcriptase inhibitor. Patients in the urban clinic received
efavirenz (EFV), lamivudine (3TC) and didanosine (ddI or ddI-EC). These regimens were
chosen because they can be co-administered with anti-tuberculosis (TB) medication. The
regimen dispensed at the rural clinic consisted of EFV, 3TC and stavudine (d4T), which is
the standard government regimen in South Africa. A few patients (3.8%) received
nevirapine (NVP) rather than EFV because they were pregnant.
All information for the CAT programme was recorded on data-collection sheets
(administered at the treatment sites) which underwent two levels of quality control and were
subsequently faxed to a data-management centre. The data used for analysis in this study
consisted of a retrospective review of the records of patients in the CAT programme
between June 2004 and September 2006. Only patient records with data on pill-count
information for the defined study period were included in the analysis. Analysis of this data
was approved by the University of KwaZulu-Natal’s biomedical research ethics committee
(ref. E 248/05).
Variables of interest
Response variable—The outcome of interest is optimal adherence to HAART. Pharmacy
records that contained the detailed pill-count information were used to calculate adherence
rates. Patients were then classified as optimally adherent if they took at least 95% of their
prescribed drugs in a given regimen; otherwise, they were considered non-adherent. Thus,
the response variable is binary, indicating whether a patient was optimally adherent or not
adherent.
Independent variables—Baseline socio-demographic variables included in the analysis
were age (years), gender, educational status, treatment site, whether or not a patient lived
with a partner, whether or not the patient was the source of household income, the patient’s
access to tap water and electricity, as well as whether or not a patient owned a cell phone.
The variables used to characterise the health status of the patients at baseline included World
Health Organization (WHO) stage of HIV disease, CD4 count (cells/μL), and weight (kg).
Information about why the HIV test was done was sought from the patients, and their
responses included being unwell, attending voluntary counselling and testing (VCT), and
various ‘other’ reasons. Other reasons included a partner having died of the disease, being ill
or being unfaithful; thus they were classified as at risk of having been exposed to HIV.
Data analysis
The socio-demographic and clinical characteristics of the study population were summarised
using the median with the inter-quartile range (IQR) for continuous variables and using
proportions for the categorical variables.
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The data were analysed by fitting a multivariate logistic regression model. The deviance was
used to compare alternative models during model selection. Change in the deviance was
used to measure the extent to which the fit of the model improved when additional variables
were included. The main effects and possible combinations of two-way interaction terms
were fitted, while attention was given to the hierarchic principle in statistical modelling. The
selected model was the one with the smallest deviance.
The selected model was assessed for goodness of fit using the Hosmer-Lemeshow statistic
(see Hosmer & Lemeshow, 1989; Collett, 2002). Influential observations were identified by
plotting the Cook’s distance statistic against the observations (see Collett, 2002). The
appropriateness of the link function was assessed by regressing the linear predictor and its
square on the dependent variable. The link function is appropriate if the linear predictor is
significant and its square is insignificant Vittinghoff, Gliden, Shiboski & McCulloch, 2005).
Results
Study population
The CAT programme enrolled 1 184 patients between June 2004 and September 2006. Pill-
count records were only available for 688 of these patients and all 688 were included in this
study. We studied relatively equal numbers of patients from each of the treatment sites, 54%
from the urban treatment site and 46% from the rural treatment site. There were no
differences in the baseline characteristics between those included in the study and those
excluded with regard to age (means: included = 34.1 years, excluded = 34 years; p = 0.90),
gender (men: included = 30%, excluded = 31.8%; p = 0.51) and baseline CD4 count (means:
included = 107.6 cells/μL, excluded = 111.5 cells/μL; p = 0.47).
Baseline socio-demographic and clinical characteristics of the patients
The baseline socio-demographic and clinical characteristics of the patients included in the
analysis are presented in Table 1. The median age of the patients was 32.5 years (inter-
quartile range [IQR]: 28–38 years), 70% were women, and 69% had attained a secondary-
school or higher level of education. A large portion of the patients were not living with a
partner (75%). Only 28% were classified as a source of their household’s income. At the
time of enrolment, 64% of the patients were classified as WHO stage 3 of HIV disease; the
sample’s median weight was 60 kg (IQR: 53–69 kg) and the median CD4 count was 108
cells/μL (IQR: 52–159 cells/μL). Over half (56%) reported that they had decided to take an
HIV test because they were not well, while 26% reported having done so because they
attended VCT. The remaining 18% said they had taken an HIV test because they felt
exposed to the risk of contracting HIV. Over 90% of the patients stayed in households that
had access to tap water and electricity, while only 42% of the patients owned cell phones. In
the first month post-HAART initiation, 79% of the patients were at least 95% adherent to
HAART.
Results of multivariate logistic regression
From a set of alternative models, a model with all the main effects and three interaction
terms had the smallest deviance and was thus selected. Goodness of fit of the model was
found to be satisfactory (Hosmer-Lemeshow statistic = 6.45; p = 0.60). The index plot of the
Cook’s distance statistic indicated that there were no influential observations. The link
function was appropriate since the linear predictor was significant (p = <0.001) while the
square of it was insignificant (p = 0.50). The adjusted odds ratios (AOR) and their
corresponding 95% confidence intervals (95% CI) for the selected model are presented in
Table 2.
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Gender, treatment site, contribution to household income, cell phone ownership, and
baseline CD4 count were all found to be significant main effects (Table 2). There were three
significant interaction terms: between age and cell phone ownership; between gender and
reported reason for taking an HIV test; and between treatment site and source of household
income. All significant main effects, except baseline CD4 count, were involved in
significant interaction terms (Table 2). For a unit increase in CD4 count (cells/μL), the odds
of HAART adherence decreased by 5% (AOR = 0.995 [0.992–0.999]; p = 0.020) (Table 2).
The interaction effects are presented in the next sections. It should be noted that for the
interaction terms that involved two categorical variables, the meaningful odds ratios for
comparison needed to be further calculated from the table of results (i.e. Table 2). The post-
hoc effects of the interactions between gender and reported reason for taking an HIV test as
well as between treatment site and the patient’s contribution to household income are
reported in Tables 3 and 4, respectively.
Interactions between patient’s age and cell phone ownership—As age increased,
optimal HAART adherence was less likely for patients without cell phone ownership than
those with cell phone ownership (AOR = 0.927 [0.869–0.987]; p = 0.019) (Table 2). More
specifically, the rate of change in optimal HAART adherence increased with age for patients
with cell phones, whereas it decreased as age increased for patients without cell phones
(Figure 1). Figure 1 shows that the gap in optimal HAART adherence between groups of
patients with and without cell phone ownership widened with increasing age.
Interactions between gender and patient’s reason for taking an HIV test—
Optimal HAART adherence was significantly higher for women than for men among
patients who reported having attended VCT as a reason for taking an HIV test (AOR = 4.911
[1.892–12.75]; p = 0.001) as well as those who reported having tested because they were not
well (AOR = 2.039 [1.066–3.900]; p = 0.031) (Table 3). There was, however, no significant
difference in optimal HAART adherence between women and men who reported having
tested for HIV because they felt exposed to the risk of contracting HIV (AOR = 0.299
[0.059–1.519]; p = 0.145) (Table 3). It is also shown that for men, HAART adherence was
significantly lower for patients who reported VCT as a reason for taking an HIV test than for
those who tested because they felt exposed to the risk of contracting HIV [AOR = 0.185
[0.035–0.993]; p = 0.049) (Table 3). These results confirm the observed proportions of
optimal HAART adherence for gender classified by reported reason for taking an HIV test
as depicted in Figure 2.
Interactions between treatment site and patient’s contribution to household
income—For patients who were not sources of their household’s income, optimal HAART
adherence was significantly higher for patients at the urban treatment site than at the rural
treatment site [AOR = 4.347 [2.258–8.369]; p = <0.001) (Table 4), whereas there was no
difference between treatment sites in regard to patients who were sources of household
income [AOR = 0.751 [0.237–2.385]; p = 0.628) (Table 4). For the rural treatment site,
optimal HAART adherence was significantly higher for patients who were a source of
household income than those who were not a source of household income (AOR = 3.828
[1.311–11.17]; p = 0.014) (Table 4; Figure 3).
Discussion and conclusions
First-month adherence to HAART decreased with increasing baseline CD4 count. It has
been previously established that healthier patients tend to have significantly greater rates of
missing appointments than immuno-compromised patients (Esch et al., 2002). Patients with
a higher CD4 count may not have experienced debilitating opportunistic infections (despite
laboratory evidence of the need to start HAART) at the time they start HAART, and this
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seems to have an adverse effect on adherence (Sarna, Pujari, Sengar, Garg, Gupta & Dam,
2008). Lack of experience of severe opportunistic infections may influence the patient’s
perceptions about the severity of the disease and the need to maintain a high level of
adherence.
Forgetfulness has been found to be the most frequently mentioned reason for missed doses
among patients on HAART (e.g. Chesney, 2000; Bartlett, 2002; Barfod, Sorensen, Nielsen,
Rodkjaer & Obel, 2006). As a result, many interventions consist of providing memory aids
for dosing times. These include the use of new technologies such as reminders through cell
phones (Bartlett, 2002; Ickovics & Meade, 2002; Abel & Painter, 2003; Osterberg &
Blaschke, 2005). Our results seem to indicate that older patients who have cell phones use
them effectively as reminders to preempt forgetfulness and thus will have higher adherence
than older patients without cell phones.
Women who had sought VCT were more likely to have adhered to their medication than
were their male counterparts. The expectation is that patients in a VCT setting are ready for
behaviour change, therefore better compliance can be expected. Lower adherence levels for
men than women who attended VCT might be attributed to the suggestion that men are less
likely to adopt positive behaviour change (Laforge, Velicer & Owen, 1999). Men who tested
for HIV because there were compelling reasons to take an HIV test tended to adhere to
medication significantly better than those who had attended VCT. In view of the general
reluctance of men to seek healthcare (Macintyre, Hunt & Sweeting, 1996; Laforge et al.,
1999), the attitudes and behaviour of the men who admitted that they had been exposed to
the risk of HIV and consequently sought healthcare might have led to higher adherence than
would be expected generally.
A major challenge facing rural communities is food insecurity, which has a negative
relationship with income (Laforge et al., 1999; Nord & Winicki, 2000). In the rural setting
we found that adherence was significantly lower among patients who were not sources of
their household’s income as compared to patients who were sources of income. Lack of food
and hunger following HAART introduction and has been a regularly cited reason for non-
adherence to HAART among patients (Marston & De Cock, 2004).
It has been shown that demographic factors are not consistently associated with adherence to
HAART (e.g. Haubrich, Little, Currier, Forthal, Kemper, Beall et al., 1999; Fong, Ho, Fung,
Lee, Tse, Yuen et al., 2003). The results from this study demonstrate that age, gender,
baseline CD4 count and contribution to household income have an effect on first-month
HAART adherence through significantly interacting with other variables, which include cell
phone ownership, reasons given by patients for taking an HIV test, and whether a patient
resides in an urban or a rural setting. We found urban versus rural differences with regard to
some of the factors that might affect first-month adherence. Due attention should be paid to
address the specific needs in each setting. It has been established that non-adherence to
treatment is associated with faster disease progression, even for those who start HAART at a
relatively high baseline CD4 count (Wood & Hogg, 2003). This, combined with lower
adherence among patients with higher CD4 counts, implies that pre-treatment counselling
interventions should also be targeted at people initiated on HAART with a relatively high
CD4 count, and should be tailored to the specific needs of these patients.
Owing to the considerable amount of information collected from the patients at the two
treatment sites for the CAT programme, as well as the quality-control measures undertaken
before the data was faxed to the data management centre, the pill-count information was
available for 688 out of 1 184 patients enrolled at the time of the analysis. However, we
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established that there were no major demographic differences between those included and
those excluded in the analysis, thus not biasing the results.
One limitation of this study is that the interactions between variables were identified using
the data and model fit techniques. The interactions were not pre-specified or expected during
data collection. Therefore, detailed information on why these interactions influenced
HAART adherence were not collected and the reason for some of these findings cannot be
explained. For example, we can only speculate about why older, but not younger, patients
who claimed cell phone ownership were found to adhere better.
Furthermore, this study focused on first-month HAART adherence and there was no
evidence that first-month HAART adherence was indicative of longer-term adherence in this
cohort. Early non-adherence to HAART has been associated with initial attrition of patients
from HIV-treatment programmes (Mocroft, Youle, Moore, Sabin, Madge, Lepri et al., 2001;
O’Brien, Clark, Besch, Myers & Kissinger, 2003) and is therefore important to understand.
An understanding of underlying factors that may contribute to non-adherence has the
potential to improve the effective scaling up of HAART programmes. The researchers
intend to further study the factors influencing long-term adherence to HAART. It would also
be interesting to see whether factors that influence first-month adherence would also
influence adherence over a longer period of time using the same dataset.
The power of this study lies in the fact that it suggests possible interactions between certain
characteristics of the patients, which merit further research. In addition, it identifies specific
groups of patients at higher risk for whom ARV adherence counselling should be targeted
and tailored.
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Log odds ratio associated with optimal HAART adherence and age for patients with and
without cell phones (based on the estimates of the coefficients from the fitted multivariate
logistic regression model).
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Percentage adherence associated with gender and reported reason for taking an HIV test
(based on observed proportions of optimal HAART adherence)
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Percentage adherence associated with treatment site and whether a patient is a source of
household income (based on observed proportions of optimal HAART adherence)
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Table 1
Baseline socio-demographic and clinical characteristics of the HAART patients (n = 688)
Characteristics Median (inter-quartile range) n (%)
Age (years) 32.5 (28–38)
Gender:
 Men 206 (30)
 Women 482 (70)
Education:
 No schooling 74 (12)
 Primaryschool 116 (19)
 Secondary school or higher 429 (69)
Treatment site:
 Urban 369 (54)
 Rural 319 (46)
Living with or without a partner:
 Living with a partner 168 (25)
 Living without a partner 510 (75)
Contribution to household income:
 Source of income 186 (28)
 Not source of income 489 (72)
WHO stage of HIV disease:
 Stage 1 71 (10)
 Stage 2 121 (16)
 Stage 3 438 (64)
 Stage 4 58 (8)
Baseline CD4 count (cells/μL) 108 (52–159)
Baseline weight (kg) 60 (53–69)
Reason for taking HIV test:
 Unwell 374 (56)
 Attended VCT 170 (26)
 Risk of exposure to HIV 121 (18)
Household access to tap water:
 Yes 611 (91)
 No 59 (9)
Household access to electricity:
 Yes 607 (91)
 No 63 (9)
Cell phone ownership:
 Yes 281 (42)
 No 389 (58)
First-month optimal HAART adherence:
 Optimally adherent 546 (79)
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Characteristics Median (inter-quartile range) n (%)
 Not optimally adherent 142 (21)













Maqutu et al. Page 15
Table 2
Adjusted odds ratios (AOR) (95% confidence interval [CI]) for the multivariate logistic regression model on
optimal HAART adherence (ref. = reference category)
Parameter AOR (95% CI) p-value
Intercept 0.422 (0.0444.024) 0.454
Age (years) 1.047 (0.992–1.106) 0.093
Gender (ref. = men)
 Women 2.039 (1.066–3.900) 0.031
Education (ref. = secondary school and above)
 No schooling 0.594 (0.277–1.276) 0.182
 Primary school 1.483 (0.725–3.033) 0.280
Treatment site (ref. = rural site)
 Urban site 4.347 (2.258–8.369) <0.001
Contribution to household income (ref. = not source of income)
 Source of income 3.828 (1.311–11.17) 0.014
Partner (ref. = living with a partner)
 Living without a partner 0.908 (0.530–1.557) 0.727
WHO stage of HIV disease (ref. = stage 4)
 Stage 1 1.575 (0.437–5.679) 0.488
 Stage 2 0.829 (0.275–2.497) 0.739
 Stage 3 0.860 (0.319–2.320) 0.766
Baseline CD4 count (cells μL) 0.995 (0.992–0.999) 0.020
Baseline weight (kg) 1.002 (0.983–1.022) 0.834
Reason for taking HIV test (ref. = unwell)
 Attended VCT 0.614 (0.271–1.389) 0.242
 Risk of exposure to HIV 3.319 (0.653–16.88) 0.143
Household access to tap water (ref. = yes)
 No 1.153 (0.473–2.811) 0.755
Household has electricity (ref. = yes)
 No 0.981 (0.441–2.184) 0.963
Cell phone ownership (ref. = yes)
 No 15.55 (1.773–136.4) 0.013
Age * cell phone ownership (ref. = own cell phone)
 Age * no cell phone ownership 0.927 (0.869–0.987) 0.019
Gender * reason for testing (ref. = men * unwell)
 Women * attended VCT 2.409 (0.767–7.566) 0.132
 Women * risk of exposure to HIV 0.147 (0.025–0.846) 0.032
Site * household income (ref. = rural site * not source of income)
 Urban site * source of income 0.173 (0.050–0.602) 0.006
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Table 3
Post-hoc effects of the interaction between gender and reported reason for taking an HIV test (adjusted odds
ratio [AOR] with 95% confidence interval [CI])
Interaction effect AOR (95% CI) p-value
Women versus men:
 Attended VCT 4.911 (1.892–12.75) <0.001
 Risk of exposure to HIV 0.299 (0.059–1.519) 0.145
 Unwell 2.039 (1.066–3.900) 0.031
Men:
 Attended VCT versus risk of exposure to HIV 0.185 (0.035–0.993) 0.049
 Attended VCT versus unwell 0.614 (0.271–1.389) 0.242
 Risk of exposure of HIV versus unwell 3.319 (0.653–16.88) 0.148
Women:
 Attended VCT versus risk of exposure to HIV 0.446 (0.073–2.739) 0.383
 Attended VCT versus unwell 1.479 (0.657–3.330) 0.345
 Risk of exposure to HIV versus unwell 3.319 (0.653–16.88) 0.148













Maqutu et al. Page 17
Table 4
Post-hoc effects of the interaction between HAART treatment site and patient’s contribution to household
income (adjusted odds ratio [AOR] with 95% confidence interval [CI])
Interaction effect AOR (95% CI) p-value
Urban versus rural treatment site:
 Source of household income 0.751 (0.237–2.385) 0.628
 Not source of household income 4.347 (2.258–8.369) <0.001
Source versus not source of household income:
 Urban site 0.662 (0.342–1.278) 0.219
 Rural site 3.828 (1.311–11.17) 0.014
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